Can you provide a SOAP note with CPT and ICD‑10 codes for a 14‑year‑old female presenting with menorrhagia, requesting combined oral contraceptive pills, and expressing concern about weight gain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

SOAP Note for 14-Year-Old Female with Menorrhagia Requesting Contraception

SUBJECTIVE

  • Chief Complaint: Heavy menstrual periods, requesting birth control pills
  • HPI: 14-year-old female presents with relative requesting oral contraceptive pills for management of menorrhagia. Reports periods occurring once monthly, lasting 5-7 days, with excessive bleeding requiring frequent pad changes due to soaking through. Denies interest in monthly injections. Expresses significant concern about weight gain and strong desire to lose weight.
  • Menstrual History: Regular cycles (monthly), duration 5-7 days, heavy flow with pad saturation
  • Past Medical History: None
  • Medications: None
  • Allergies: Not documented
  • Sexual History: Not documented in note
  • Contraceptive Goals: Menorrhagia management and contraception

OBJECTIVE

  • Vital Signs:
    • Temperature: 97.8°F
    • Heart Rate: 77 bpm
    • Respiratory Rate: 18/min
    • Blood Pressure: 102/61 mmHg
    • Height: 5'1" (61 inches)
    • Weight: 113 lbs
    • BMI: 21.4 kg/m² (healthy weight range)

ASSESSMENT

Primary Diagnosis: Menorrhagia (heavy menstrual bleeding)

Secondary Considerations:

  • Contraceptive counseling
  • Weight concerns/body image concerns

PLAN

Combined oral contraceptive pills are the appropriate first-line treatment for this adolescent with menorrhagia, as they effectively reduce menstrual blood loss by 34-87% and are weight-neutral despite common misconceptions 1, 2.

Medication Management

Prescribe low-dose combined oral contraceptive (≤35 mcg ethinyl estradiol) 3. The evidence strongly supports:

  • COCs increase treatment success from 3% (placebo) to 12-77% in women with heavy menstrual bleeding 1
  • No reliable evidence links COCs to weight gain—this is a well-documented myth 3, 2. Weight perception is often due to:
    • Fluid retention from estrogen's effect on the renin-angiotensin-aldosterone system (not fat gain)
    • Misattribution of normal age-related weight changes
    • Nocebo effect

Counseling Provided (Documented)

Weight Gain Education:

  • Extensive counseling provided regarding weight neutrality of combined oral contraceptives
  • Explained that COCs do not cause fat accumulation 2
  • Discussed that DMPA (depot injection) is the only hormonal contraceptive with verified weight gain risk—which she has already declined 2
  • Addressed body image concerns and healthy weight status (BMI 21.4)

Contraceptive Education:

  • Quick-start method acceptable (can begin today) 3
  • Use backup contraception (condoms or abstinence) for first 7 days 3
  • Condoms required at all times for STI protection
  • Common transient side effects: irregular bleeding (first 3 months), headache, nausea 3
  • Missed pill instructions per CDC guidelines 3

Expected Benefits:

  • Significant reduction in menstrual blood loss 1
  • Regular, predictable cycles
  • Contraceptive efficacy (0.3% perfect use failure rate; 9% typical use) 3

Follow-Up

  • Return visit in 1-3 months to assess:
    • Menstrual bleeding improvement
    • Adverse effects management
    • Adherence strategies
    • Weight stability reassurance
  • Consider hemoglobin/ferritin if bleeding does not improve or if anemia suspected

Alternative Considerations if COCs Fail

  • Levonorgestrel IUD (LNG-IUS) is more effective than COCs for menorrhagia (87% vs 35% reduction in blood loss) but requires insertion procedure 4
  • NSAIDs (5-7 days during menses) can be added if breakthrough bleeding persists after 3 months 5
  • Formulation change (different progestin or estrogen dose) if side effects problematic 3

Safety Screening

  • No contraindications identified (no hypertension, thrombophilia, migraines with aura, hepatic dysfunction, or other absolute contraindications) 3
  • Pelvic examination NOT required before COC initiation 3
  • STI screening recommended if/when sexually active

CPT CODES

  • 99213 - Office/outpatient visit, established patient, 20-29 minutes (moderate complexity medical decision-making for contraceptive counseling and menorrhagia management)
    • Alternative: 99214 if visit duration 30-39 minutes with extensive counseling documented
  • 99401 or 99402 - Preventive medicine counseling (15-30 minutes) for contraceptive education and weight concerns (may be used in addition if time supports)

ICD-10 CODES

  • N92.0 - Excessive and frequent menstruation with regular cycle (menorrhagia)
  • Z30.011 - Encounter for initial prescription of contraceptive pills
  • Z71.89 - Other specified counseling (for weight/body image concerns)

Clinical Pearls

  • The weight gain concern is the #1 reason adolescents discontinue effective contraception—aggressive, evidence-based counseling is critical 2
  • Reassurance during first 3 months of irregular bleeding prevents discontinuation 5, 6
  • Cell phone alarms and family support improve adherence 3
  • This patient's healthy BMI (21.4) should be explicitly reinforced to address body image concerns

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.